On October 23, 2026, Oaktree Acquisition Corp. III Life Sciences (“OAC”) issued 4,798,758 Class A ordinary shares, par value $0.0001 per share to Oaktree Acquisition Holdings III LS, LLC, a Cayman Islands limited liability company (the “Sponsor”) upon conversion (the “Conversion”) by the Sponsor of its 4,798,758 Class B ordinary shares, par value $0.0001 per. Following the Conversion, the Sponsor is holding 5,382,739 Class A ordinary shares (including 583,981 private placement shares included in the private placement units that the Sponsor purchased from OAC in connection with OAC’s initial public offering) and 1,000 Class B ordinary shares. The 4,798,758 Class A ordinary shares issued in connection with the Conversion are subject to the same restrictions as applied to the Class B ordinary shares before the Conversion, including, among other things, certain transfer restrictions, waiver of redemption rights and the obligation to vote in favor of an initial business combination as described in OAC’s final prospectus for its initial public offering.
|
Oaktree Acquisition Corp. III Life Sciences is a blank check company formed to effect a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company intends to focus on the healthcare or healthcare-related industries, specifically targeting North American, British or European companies in the biopharmaceutical, medical devices, diagnostics, and specialized healthcare services sectors. It is sponsored by an affiliate of Oaktree Capital Management L.P. The management team includes Dr. Aman Kumar and Zaid Pardesi, who have prior experience with Oaktree’s previous special purpose acquisition companies that completed business combinations with Hims & Hers Health, Inc. and Alvotech. The company completed its initial public offering in October 2024 and has not yet selected a specific business combination target. Summarised from the company's own disclosures, fiscal year ended Mar 2026 |
Industry Shell Companies | Homepage oaktreeacquisitioncorp.com/oac-iii |
| Sector Financial Services | IR page — | |
|
Tags
blank check company, special purpose acquisition company, life sciences, healthcare, biopharmaceutical, medical devices, diagnostics, healthcare services, Oaktree Capital Management L.P., Hims & Hers Health Inc., Alvotech, Oaktree Acquisition Corp., Oaktree Acquisition Corp. II
|
Press page — |
Metrics
| Valuation | |
|---|---|
| Market cap | $ 264.511M |
| Market cap (USD) | $ 264.511M |
| P/E | 61.02 |
| PEG | — |
| P/BV | -27.50 |
| P/S | — |
| P/OCF | -438.48 |
| P/FCF | -626.69 |
| Dividend yield | — |
| Turnover / mcap | — |
| Returns | |
|---|---|
| ROE | -107.7% |
| ROI | — |
| ROIC | — |
| Profit margin | — |
| Growth | |
|---|---|
| Revenue growing | — |
| Profits growing | — |
| Revenue up 3y | — |
| Revenue up 5y | — |
| Earnings growth 3y (net profit CAGR) | — |
| Quality | |
|---|---|
| Profitable | Yes |
| Margin expanding | — |
| Buying back stock | — |
| Diluting (TTM) | No |
| Debt/Equity | — |
| Podcast bulls (TTM) | Sign up |
| Podcast bears (TTM) | Sign up |
| Podcast sentiment (TTM) | Sign up |
| Podcast sentiment % (TTM) | Sign up |
| News sentiment (TTM) | 0 |
| Quality score | -50.0% |
| Insiders | |
|---|---|
| Buys, 1w | Sign up |
| Buys, 1m | Sign up |
| Buys, 1y | Sign up |
| Sells, 1w | Sign up |
| Sells, 1m | Sign up |
| Sells, 1y | Sign up |
Sign up to see this company's insider trades
Filed figures
Lines the statements and their notes report beside the headline figures, read from the filings' XBRL as filed (no restatement applied), with figures computed from one filing's own lines. Cash-flow lines carry their cash direction: an outflow is negative. Each period links to its filing; a figure's period, report date and tag are in its tooltip.
Sign up to see institutional holdings
Sign UpPodcast Mentions
Sign up to see podcast mentions and sentiment
Sign UpNews
Material events reported to the SEC on Form 8-K or 6-K, newest first. The link opens the filing itself on EDGAR.
Postponement of General Meeting to October 23, 2026 On October 2, 2026, Oaktree Acquisition Corp. III Life Sciences (“OAC”) filed a definitive proxy statement (the “Extension Proxy Statement”) for an extraordinary general meeting in lieu of an annual meeting of its shareholders to be held on October 16, 2026 (the “General Meeting”) to consider and act upon a proposal to extend the date by which OAC must complete an initial business combination (a “Business Combination”). On October 16, 2026, the extension committee of the board of directors of OAC (the “Board”) approved the postponement of the General Meeting, prior to the time at which it was scheduled to be held, to October 23, 2026 (such meeting, the “Rescheduled General Meeting”) in order to permit further solicitation and vote of proxies. The Rescheduled General Meeting will be held on October 23, 2026, at 10:00 a.m., Eastern Time, at the offices of Kirkland & Ellis LLP located at 601 Lexington Avenue, New York, NY 10022, and via a virtual meeting, or at such other time, on such other date and at such other place to which the meeting may be postponed or adjourned.
Preliminary Redemption Results On October 2, 2026, Oaktree Acquisition Corp. III Life Sciences (“OAC”) filed a definitive proxy statement (the “Extension Proxy Statement”) for an extraordinary general meeting in lieu of annual meeting of its shareholders to be held on October 16, 2026 to consider and act upon a proposal to extend (the “Extension”) the date by which OAC must complete an initial business combination (a “Business Combination”). As set forth in the Extension Proxy Statement, the deadline by which OAC public shareholders had to complete the procedures for electing to redeem their Class A ordinary shares, par value $0.0001 per share, of OAC (the “Class A ordinary shares”) was 5:00 p.m., Eastern Time, on October 14, 2026 (the “Redemption Deadline”). The number of Class A ordinary shares tendered for redemption prior to the Redemption Deadline was 13,326,977 Class A ordinary shares.
Prompts
Click prompts to add them under the company line, click again to take one out, then copy the result into your AI chat. Shared by Asian Century Stocks and Uncovered Thai Stocks. Thank you.
ETFs Holding Oaktree Acquisition Corp. III Life Sciences
Exchange-traded funds whose newest published daily portfolio holds one of the company's listings, largest weight first.
| ETF | Weight in ETF | Shares | Market value | As of |
|---|---|---|---|---|
| SPAQ | 5.31% | 50,006 | $ 535.564K | Jun 30, 2026 |